Thank you to Loyola Medicine Mentor, Dr. Jamie Berkes, and Fellows, Dr. Laura Nunez-Herrero and Dr. Irfan Rahman
3
Thank you to University of Illinois Mentor, Dr. Adam Mikolajczyk and Fellows, Dr. Wasseem Skef and Dr. Mitali Agarwal
Loyola Medicine will argue that TARE should be the primary locoregional therapy for unresectable HCC
2
The University of Illinois will argue, TACE should be the primary locoregional therapy for unresectable HCC
Cook County Health will argue the Con position that all patients with immune tolerant HBV do not need to be treated
1
